Overview of Morphgesic SR

Property	Description
Active Ingredient	Morphine Sulfate (INN)
Form	Controlled-release Oral Tablet
Pharmacological Class	Strong Opioid Analgesic
General Purpose	Management of severe, persistent pain
Origin	Semi-synthetic derivative of an Opium Alkaloid

Defining Morphgesic SR: Active Ingredient and Pharmacological Class

Morphgesic SR is a prescription-only medicine classified as a strong Opioid Analgesic, indicated for the management of severe, persistent pain. Its active component is Morphine Sulfate, which originates from a class of compounds derived from the natural Opium Alkaloids of the Papaver somniferum plant. This drug is part of the highest tier of available pain relievers and is strictly reserved for use when less potent analgesics are insufficient. Morphine acts primarily on the mu-opioid receptor to produce pain relief by selectively activating specific opioid receptors in the central nervous system, thereby interrupting and mitigating the perception and transmission of intense pain signals. Morphine-based analgesia is a standard treatment for severe pain requiring opioid intervention.

What Does the "SR" in Morphgesic SR Mean?

The letters "SR" in Morphgesic SR signify Sustained Release, confirming that the drug is formulated as a specialized oral tablet designed for prolonged action. This dosage form is also officially designated as a Controlled-release or Extended-release tablet. The formulation is engineered with an internal matrix system that strictly controls the rate at which Morphine Sulfate dissolves and enters the bloodstream. Modified-release formulations are used to maintain stable plasma concentrations and therapeutic effects over a prolonged period. This controlled-release design distinguishes it from immediate-release morphine products.

General Purpose: Prolonged Analgesia for Severe Pain

The general purpose of Morphgesic SR is to provide continuous, long-acting pain relief over an extended dosing interval, typically lasting up to 12 hours. This stable control is the central benefit derived from combining the potency of a strong opioid with a regulated sustained-release system. The design makes the medication highly suitable for individuals, such as those with chronic malignant or non-malignant pain, who experience persistent, severe pain that requires predictable, round-the-clock management. The extended-release profile helps stabilize the patient's baseline comfort level throughout the day and night.

Regulatory References

MedlinePlus Information

What side effects are possible with Morphgesic SR?

Official Adverse Effects and Safety Profile

The safety profile for Morphgesic SR (Morphine Sulfate controlled-release) is formally documented in government regulatory labeling, categorizing adverse reactions by frequency and affected body system. This section presents only the facts and classifications derived from official sources.

Frequency-Classified Side Effects

Adverse reactions are classified according to their rate of occurrence in clinical data:

Frequency Category	Key Documented Adverse Reactions
Very Common (ge 10% of patients)	Constipation, Nausea, Somnolence (Drowsiness), Sweating
Common (1% to < 10% of patients)	Dizziness, Headache, Vomiting, Pruritus (Itching), Dry mouth, Confusion
Uncommon / Rare	Respiratory depression, Hypotension, Tachycardia, Urinary retention, Agitation

Serious Adverse Reactions

The most critical and potentially life-threatening risks explicitly highlighted in regulatory safety sections include Respiratory Depression and Circulatory Depression (including severe hypotension). The label also notes the risks of Severe Hypotension and Neonatal Opioid Withdrawal Syndrome if used during pregnancy.

Safety Constraints and Population Notes

Contraindications: The medicine must not be used in individuals experiencing significant respiratory depression, paralytic ileus (bowel obstruction), or in those using Monoamine Oxidase Inhibitors (MAOIs).

Time- and Population-Related Risks: The risk of Respiratory Depression is documented as being greatest during treatment initiation or following a dosage increase. Older Adults and patients with Renal or Hepatic Impairment are noted to be at increased risk for adverse effects. Tolerance and Physical Dependence are recognized as associated with long-term exposure.

Overdose and Emergency Response

The official regulatory profile for Morphgesic SR (Morphine Sulfate) overdose emphasizes severe, potentially fatal outcomes and mandates immediate emergency action.

Property	Official Regulatory Statement
Documented Overdose Presentations	Symptoms include respiratory depression (slow, shallow breathing), pinpoint pupils (miosis), somnolence progressing to stupor or coma, and skeletal muscle flaccidity.
Physiological Systems Affected	Primarily the Central Nervous System and Respiratory system; secondary effects involve the Circulatory system leading to hypotension.
Dose-Related Factors	Accidental ingestion of even one dose of this extended-release formulation can result in a fatal overdose.
Emergency-Response Statements	Naloxone is the specific opioid antagonist indicated for the reversal of respiratory depression. Resuscitative equipment, including Naloxone, should be immediately available.

Classification	Official Regulatory Statement
Severity Classification	Overdose can lead to life-threatening respiratory depression, circulatory depression, and death.
When Immediate Medical Help is Required	Seek immediate medical attention at once if an overdose is suspected, or call 911 (emergency services) if the person has stopped breathing.

Official Overdose Statements:

Overdose is characterized by profound CNS depression, particularly pinpoint pupils and progression from somnolence to unresponsiveness.
The life-threatening severity is driven by profound respiratory depression leading to apnea, shock, and the risk of death.
Management procedures include the use of the specific antagonist Naloxone and the provision of symptomatic and supportive treatment, including measures to maintain airway patency.

The regulatory documents define the overdose profile by detailing the life-threatening potential inherent to the strong opioid classification, specifically emphasizing severe respiratory depression. These documents mandate that the occurrence of these documented clinical manifestations requires immediate emergency medical attention.

Therapeutic Uses of Morphgesic SR

What Morphgesic SR Treats: Main Uses and Benefits

This medication is applied across therapeutic domains requiring supportive relief for symptoms related to physical discomfort. The therapeutic domain for this medication involves symptoms that are severe and persistent, and is used in clinical settings that involve an ongoing need for symptomatic assistance.

Morphgesic SR is commonly used for managing severe, persistent pain associated with conditions like advanced illnesses, cancer, and severe chronic non-cancer conditions. This approach is considered when symptoms are not adequately managed by alternative treatment options.

The Sustained-Release (SR) formulation is applied across therapeutic domains that require continuous support for pain management. This continuous approach assists with maintaining a sense of stability when symptoms are more noticeable and assists with maintaining functional stability. The medication is used for managing symptoms that create noticeable functional strain, such as difficulty with mobility or sleep.

“This supportive relief may help patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort.”

Quick Fact: Relief for Persistent Pain The sustained-release profile supports the management of baseline chronic discomfort over an extended interval, and plays a role in managing symptoms across a prolonged period.

Eligibility and Restrictions for Use

Morphgesic SR (Morphine Sulfate Sustained Release) is officially approved for use in Adult Patients who require daily, around-the-clock opioid analgesia for severe, persistent pain [FDA Label; EMA SmPC].

Contraindicated Populations (Must Not Use)

Regulatory agencies strictly prohibit use (contraindicate) in individuals with specific conditions, including:

Significant Respiratory Depression or acute/severe bronchial asthma in unmonitored settings.
Known or Suspected Paralytic Ileus or other gastrointestinal obstruction.
Hypersensitivity to morphine or any component of the formulation.
Concurrent use of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOIs [FDA Label; EMA SmPC].

Age-Specific and Conditional Eligibility

Population	Official Regulatory Status
Pediatric Patients (lt 18)	Not established and not recommended for use [FDA Label].
Pregnancy	Not recommended; prolonged use carries the risk of Neonatal Opioid Withdrawal Syndrome [FDA Label].
Lactation	Not recommended due to morphine excretion into breast milk [EMA SmPC].
Severe Organ Impairment	Conditional use; caution is required in patients with severe renal or hepatic impairment due to risk of accumulation [FDA Label; EMA SmPC].

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details officially documented interaction patterns for Morphine Sulfate (Morphgesic SR) strictly as reported in government regulatory documents.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated (prohibited). Official labeling dictates a mandatory separation of at least 14 days after stopping MAOI treatment before initiating Morphgesic SR.

Pharmacodynamic Interactions

Concomitant use with Central Nervous System (CNS) depressants, including other opioids, benzodiazepines, sedatives, and general anesthetics, may result in additive CNS depressant effects. This pharmacodynamic interaction increases the potential for profound sedation and severe respiratory depression.

Using Mixed Agonist/Antagonist Opioid Analgesics (e.g., Butorphanol, Buprenorphine) must be avoided, as this combination is officially documented to potentially reduce the analgesic effect or precipitate withdrawal symptoms.

Co-administration with certain Serotonergic Drugs has been linked in regulatory documentation to the risk of serotonin syndrome.

Exposure Modification and Substances

Interaction with substances that modify drug exposure is officially noted. Co-administration with Rifampicin may reduce the plasma concentrations of morphine. Conversely, agents like Cimetidine and P-glycoprotein (P-gp) Inhibitors are documented to potentially increase the plasma concentrations of morphine. Consumption of alcohol is restricted due to the potential for a rapid release of the active ingredient from the sustained-release formulation, leading to dangerously high systemic exposure.

Population-Specific Notes

The risk of severe respiratory depression resulting from interaction with CNS depressants is specifically noted to be higher in elderly, cachectic, or debilitated patients.

Mechanism of Action

Mu-Opioid Receptor Activation

Morphgesic SR (morphine sulfate) acts as a selective agonist by binding to and activating the mu-opioid receptors (mu-OR), which are distributed throughout the central nervous system, including the spinal cord and brain. This interaction initiates an inhibitory signaling cascade at the cellular level, which determines the foundational mechanism of the drug's effect profile.

Dampening Neural Signal Transmission

Activation of the mu-OR leads to the engagement of Gi/Go proteins, causing two key actions on nerve cells: reducing the release of excitatory neurotransmitters from the presynaptic neuron and hyperpolarizing the postsynaptic neuron. These actions effectively limit the signaling capacity of affected pathways, affecting the dynamics of overactive physiological signaling. The drug modifies the activity level within targeted systems, which contributes to the observed physiological effect profile through central pathway modulation.

Dosage and Administration Information

How to Use Morphgesic SR

The administration of Morphgesic SR is designed to provide continuous, sustained relief. This medicine is a Controlled-release Oral Tablet intended for ingestion only.

Official Dosing and Scheduling Principles

The standard frequency for this sustained-release formulation is twice daily, administered at strict 12-hourly intervals on a fixed schedule. This fixed timing is necessary to maintain consistent levels of the active ingredient, making the product unsuitable for 'as-needed' pain management.

Treatment initiation for opioid-naïve adults typically begins with a low dose, such as 10 mg or 15 mg. The subsequent dosing is determined by titration, a process of gradually adjusting the amount to achieve appropriate pain management. Once established, the regimen is for long-term use; discontinuation of the medicine requires a gradual dose taper.

Administration Requirements

Procedural Requirement	Official Instruction
Physical Handling	The tablet must be swallowed whole.
Prohibited Actions	Do not chew, crush, break, or dissolve the tablet, as this defeats the controlled-release mechanism.
Timing in Relation to Meals	May be taken with or without food.
Missed Dose	If a dose is missed, take the next dose at the usual scheduled time; do not take a double dose.

Population-Specific Dosing

Cautious dosing is required for certain patient populations. For older adults and patients with known renal or hepatic impairment, the treatment must generally be initiated at a lower starting dose. The controlled-release tablets are officially not recommended for pediatric use.

Recent Clinical Evidence

Morphgesic SR: Recent Clinical Evidence

The following summary outlines the findings from clinical research that have investigated the use and profile of sustained-release (SR) morphine formulations, such as Morphgesic SR.

Primary Efficacy Studies

Initial research examined the drug's properties and its relation to blood pressure metrics, focusing on its influence on blood vessel activity. Clinical trials assessed potential changes in pain scores among individuals with chronic pain, including those with advanced cancer. These studies typically involved double-blind, randomized, placebo-controlled designs to evaluate outcomes against a non-active comparator.

Tolerability, Long-Term Data, and Comparative Research

Research Focus	Key Findings Evaluated
Tolerability Profile	Reported side effects were characterized by investigators in terms of their frequency and intensity. Investigators noted that the most commonly reported events included dizziness, constipation, and fatigue.
Chronic Pain Management	Studies have assessed whether SR formulations, administered every 12 hours, can maintain comparable pain control to immediate-release formulations given more frequently in hospitalized patients with chronic cancer pain.
Long-Term Assessment	Changes in reported pain levels were evaluated during follow-up periods, sometimes extending up to 12 months. This assessment was often performed in open-label extension studies following initial trials.
Subgroup Analysis	The findings highlight the study of specific results for individuals with kidney disease, with specific data points evaluating changes in estimated glomerular filtration rate (eGFR).

Note on Off-Label Use: Research has also explored the use of low-dose SR morphine for other conditions, such as chronic refractory breathlessness, in randomized trials. However, this is outside the drug's primary indication for severe, persistent pain requiring daily, around-the-clock opioid treatment.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Morphgesic SR (FAQ)

Q: How is Morphgesic SR different from immediate-release morphine?

Morphgesic SR is a long-acting formulation specifically designed to provide scheduled, around-the-clock pain relief. This is distinct from immediate-release morphine, which is generally used for acute, short-term pain episodes, such as breakthrough pain, and is not suitable for routine, scheduled long-term management. This difference is based on the drug's sustained-release mechanism.

Q: How long does the pain relief from Morphgesic SR typically last?

The sustained-release formulation is engineered to provide consistent pain relief over an extended duration. According to official product information, it is designed to last up to 12 hours, which supports the requirement for administration on a fixed, scheduled basis to maintain stable medication levels.

Q: What is the onset of action for Morphgesic SR?

The onset of the analgesic effect for oral sustained-release morphine is typically observed within 30 to 60 minutes after ingestion. Because it is a sustained-release product, the full, steady therapeutic benefit is achieved after several doses have been taken regularly and on schedule.

Q: Can Morphgesic SR be used by people with kidney impairment, according to official guidelines?

Official regulatory guidelines indicate that caution is necessary for patients with renal (kidney) impairment. Due to the potential risk of the active ingredient accumulating in the body, treatment must generally be initiated with a lower starting dose and may be subject to close monitoring.

Q: Does the body develop a physical tolerance to Morphgesic SR over time?

Yes, regulatory documents recognize physical tolerance as an expected physiological effect associated with the long-term use of Morphgesic SR and other opioid medicines. Tolerance means the body adjusts to the medication, which is a factor to be considered in treatment effectiveness.

Q: Are withdrawal symptoms possible when stopping Morphgesic SR?

Yes, a withdrawal syndrome is possible if the medicine is suddenly or abruptly discontinued after a patient has been using it long-term. This potential for withdrawal is the reason official prescribing information mandates a gradual dose reduction when treatment is stopped.

Q: What steps are outlined in official documents for stopping Morphgesic SR?

Official documents strictly mandate that the medicine must be discontinued using a gradual dose taper, meaning the amount of medicine is reduced slowly over time. This approach is described to help mitigate the risk of withdrawal symptoms in physically dependent patients.

Q: Can Morphgesic SR be safely used by older adults?

Official labels require cautious use for older adults due to their increased sensitivity to opioid effects. Treatment must generally be initiated with a lower starting dose because older individuals are noted to be at increased risk for adverse effects, particularly respiratory depression.

Q: What are the research findings regarding the long-term effectiveness of Morphgesic SR?

Clinical trials have investigated the long-term use of sustained-release morphine for periods such as up to 12 months. Studies have reported findings that include significant and sustained improvement in pain scores and quality of life for individuals with moderate-to-severe chronic pain requiring continuous opioid management.

Q: Does Morphgesic SR interact with common anxiety or depression medications?

Official interaction warnings are noted for certain classes of these medicines. Concurrent use with CNS depressants (including some anxiety medicines) can increase the risk of profound sedation. Using it with Serotonergic Drugs (including many antidepressants) may increase the risk of a condition known as serotonin syndrome.

Q: What is the approved duration of use for Morphgesic SR, according to regulatory bodies?

The medicine is approved for the management of pain that requires daily, around-the-clock, long-term opioid treatment. Regulatory bodies do not specify a single maximum duration, as the length of use is based on the individual patient's severity of pain and clinical needs.

Q: Are there any specific mental health side effects listed for Morphgesic SR?

Yes, regulatory adverse reaction reports include mental or neurological effects. Official labels list effects such as confusion, disorientation, and agitation as reported side effects that patients may experience.

Q: Does Morphgesic SR interact with common over-the-counter pain medications?

Regulatory guidance primarily focuses on prescription drug interactions, but caution is given for any over-the-counter (OTC) medicines. While non-opioid OTC relievers like ibuprofen are generally not prohibited, any OTC medicine containing opioids (such as codeine) or CNS depressants may present an increased risk of side effects.

Q: What types of foods or supplements might interact with Morphgesic SR?

The most important restriction noted in official labels is the complete avoidance of alcohol due to the risk of rapid drug release. There are generally no specific interactions listed for common foods; however, consultation regarding any herbal products or supplements is generally recommended before use.

Q: Is Morphgesic SR appropriate for chronic non-cancer pain, as described in research?

The medicine is officially approved for severe, persistent pain which includes both chronic malignant (cancer-related) and chronic non-malignant pain. The key requirement is that the pain must be severe enough to necessitate around-the-clock opioid management where alternative options are inadequate.

Q: What is the difference between physical dependence and addiction for this medicine?

Regulatory and medical information draws a distinction between these two concepts. Physical dependence is a normal physiological adaptation that causes withdrawal symptoms if the drug is suddenly stopped. Addiction (Opioid Use Disorder) is a chronic disease characterized by the compulsive, harmful use of the substance despite negative outcomes.

Q: What is the risk classification of Morphgesic SR regarding driving or operating machinery?

Official labels include an explicit warning concerning the risk to motor and cognitive function. The medicine may impair the mental and/or physical abilities required to safely perform hazardous tasks such as driving a car or operating heavy machinery.

Q: Does Morphgesic SR affect hormone levels?

Yes, chronic opioid use, including Morphgesic SR, is noted in regulatory information as potentially affecting the endocrine system. Official labels report that opioids may inhibit the secretion of certain hormones, such as cortisol and luteinizing hormone (LH).

Q: Can Morphgesic SR cause a skin rash or allergic reaction?

Yes, the official label lists skin rash and urticaria (hives) as reported adverse reactions that patients may experience. While these are usually uncommon, severe allergic reactions (anaphylaxis) are also noted as a rare but possible risk.

Q: What information is available about the effectiveness of Morphgesic SR in children?

According to official regulatory documents, the medicine's safety and effectiveness are not established in pediatric patients (under 18 years of age). Due to the lack of sufficient data, the medicine is officially not recommended for use in this population.

Q: Where can I find the official prescribing information (SmPC/DailyMed) for Morphgesic SR?

The complete official prescribing information is publicly available through governmental sources. This information can be found on the DailyMed website in the U.S. and the Summary of Product Characteristics (SmPC) accessible via regulatory bodies in Europe like the MHRA or EMA.

Q: Are there any known drug interactions between Morphgesic SR and blood thinners?

While the label does not universally contraindicate the medicine with all blood thinners (anticoagulants), co-administration may require monitoring. Co-administration may be discussed with a healthcare professional to ensure appropriate management.

Q: What evidence exists for using Morphgesic SR in post-operative pain management?

The medicine is specifically indicated for severe pain requiring around-the-clock, long-term treatment. Extended-release opioids are generally not recommended for routine, short-term acute pain, such as typical post-operative pain.

Q: What is the maximum daily amount of Morphgesic SR described in official sources?

Official documents emphasize the importance of individual titration to an effective dose. There is no single, fixed maximum daily dose described in official sources; instead, the appropriate maximum dose is based on the patient's existing opioid tolerance and the judgment of the prescribing clinician.

Q: Why do official documents warn against abrupt discontinuation of Morphgesic SR?

The warning exists because abruptly stopping the medication can precipitate opioid withdrawal symptoms in physically dependent patients. This action may also lead to a rapid return of severe pain, which the sustained-release medicine was intended to manage.

How should Morphgesic SR be stored and disposed of?

How to Store and Dispose of Morphgesic SR

Morphgesic SR (Morphine Sulfate Extended-Release Tablets) must be stored strictly according to regulatory standards to ensure product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Do not store mathbfabove 25 C or store at 20 C-25 C.
Protection	Protect from light and moisture and keep in the original package.

Child Safety and Handling

Secure storage is mandatory. The product must be kept out of the sight and reach of children to prevent accidental ingestion, which can result in a fatal overdose. The tablets must not be crushed, chewed, or broken.

Disposal Instructions

Dispose of unused or expired Morphgesic SR according to local regulations for pharmaceutical waste. Official guidance directs consulting sources like the FDA for safe disposal methods, which may include using drug take-back programs.

Morphgesic SR